-
Mashup Score: 2Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-line Treatment of KRAS-mutant Metastatic Colorectal Cancer: A Phase 1b Clinical Study - 3 month(s) ago
Abstract. Purpose: Onvansertib is a highly specific inhibitor of Polo-like kinase 1 (PLK1), with demonstrated safety in solid tumors. We evaluated, preclinically and clinically, the potential of onvansertib in combination with chemotherapy as a therapeutic option for KRAS-mutant colorectal cancer (CRC). Patients and Methods: Preclinical activity of onvansertib was assessed: (1) in vitro in KRAS-wild type and -mutant isogenic CRC cells; and (2) in vivo, in combination with irinotecan, in a KRAS-mutant xenograft model. Clinically, a Phase Ib trial was conducted to investigate onvansertib at doses 12, 15, and 18 mg/m2 (days 1-5 and 14-19 of a 28-day cycle) in combination with FOLFIRI/bevacizumab (days 1 and 15) in KRAS-mutant metastatic CRC patients who had prior oxaliplatin exposure. Safety, efficacy, and changes in circulating tumor DNA (ctDNA) were assessed. Results: In preclinical models, onvansertib displayed superior activity in KRAS-mutant than wild-type isogenic CRC cells and demo
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 45Risk factors for early-onset pancreatic ductal adenocarcinoma: a systematic literature review - 5 month(s) ago
Emerging cancer trends suggest an increase in pancreatic cancer incidence in individuals younger than its typical age of onset, potentially reflecting…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet-
Risk factors for early-onset #PancreaticCancer : a syste... https://t.co/Qm74pcTe0b
-
-
Mashup Score: 45Risk factors for early-onset pancreatic ductal adenocarcinoma: a systematic literature review - 5 month(s) ago
Emerging cancer trends suggest an increase in pancreatic cancer incidence in individuals younger than its typical age of onset, potentially reflecting…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet-
Risk factors for early-onset #PancreaticCancer : a syste... https://t.co/Qm74pcTe0b
-
-
Mashup Score: 22Risk factors for early-onset pancreatic ductal adenocarcinoma: a systematic literature review - 5 month(s) ago
Emerging cancer trends suggest an increase in pancreatic cancer incidence in individuals younger than its typical age of onset, potentially reflecting…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet-
Risk factors for early-onset #PancreaticCancer : a syste... https://t.co/Qm74pcTe0b
-
-
Mashup Score: 19Risk factors for early-onset pancreatic ductal adenocarcinoma: a systematic literature review - 5 month(s) ago
Emerging cancer trends suggest an increase in pancreatic cancer incidence in individuals younger than its typical age of onset, potentially reflecting…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet-
Risk factors for early-onset #PancreaticCancer : a syste... https://t.co/Qm74pcTe0b
-
-
Mashup Score: 2HCC-LIVE Conference Registration | HCC-LIVE - 5 month(s) ago
The HCC-LIVE Conference will bring together key opinion leaders from teams of clinicians who care for patients with HCC (oncologists, hepatologists, gastroenterologists, interventional radiologists, and surgeons) from the industry to discuss optimized trial design, patient populations, therapeutic endpoints, and potential benefits these agents can have for patients with HCC. The 1.5-day meeting will maintain core tenants such as debate, tumor boards, multidisciplinary discussion, a highlight of top papers and new technologies, symposia, and special focus sessions on local and systemic therapies, all anchored in multidisciplinary representation (hepatology, medical, surgical, and radiation oncology, diagnostic and interventional radiology, transplant surgery) with time dedicated to robust discussions.
Source: www.hcc-live.orgCategories: General Medicine News, Hem/OncsTweet-
RT @HCCLIVEConf: Course Director Spotlight: Join @JulieHeimbach, MD at the HCC-LIVE Conference - Register Now! https://t.co/N5d0siBgod #HC…
-
-
Mashup Score: 24
What is this summary about? This is a summary of an article describing an ongoing study called MOUNTAINEER. This article was published in The Lancet Oncology in 2023. The study included 117 adults with metastatic HER2-positive colorectal cancer. The researchers wanted to know whether a combination of 2 drugs called tucatinib and trastuzumab could shrink the participants’ cancer. The researchers also wanted to know whether receiving tucatinib alone could also shrink the participants’ cancer. What were the results? In this study, researchers found that 32 out of 84 participants had their tumors respond to treatment with tucatinib with trastuzumab. This was about 4 in 10 participants. This means that the tumors shrank by at least 30% or disappeared. Participants whose tumors responded to tucatinib with trastuzumab responded for a median of 12.4 months. 60 out of 84 participants had their tumors respond or remain about the same size after treatment with tucatinib with trastuzumab. This was
Source: www.futuremedicine.comCategories: General Medicine News, Hem/OncsTweet-
A study to learn how well #tucatinib plus #trastuzumab works for treating participants with metastatic #colorectalcancer, and how safe it is: a plain language summary of the MOUNTAINEER study https://t.co/07LFq94Y9k
-
-
Mashup Score: 39Mayo Clinic Hepato-Pancreatico-Biliary Cancer Symposium 2023 | Mayo Clinic School of Continuous Professional Development | CME Course Conference - 7 month(s) ago
November 10 – 11, 2023 – Encore at Wynn Las Vegas – Las Vegas, Nevada This course offers Live (in-person) and Livestream (virtual) attendance options The 2023 Mayo Clinic Hepato-Pancreatico-Biliary Cancer Symposium provides a multidisciplinary overview on the importance of early diagnosis and treatment considerations, including surgery, radiation, loco-regional approaches, and
Source: ce.mayo.eduCategories: General Medicine News, Hem/OncsTweet-
Join our outstanding @MayoCancerCare and guest faculty on Nov 10-11 in Las Vegas (or via livestream) for 2023 Mayo Clinic #livercancer #pancreascancer #cholangiocarcinoma Symposium! Registration information and the program schedule are available here: https://t.co/aCIcCwqDxy https://t.co/nWEx0fXv7r
-
-
Mashup Score: 1HOME - 20th Annual Meeting of the International Society of Gastrointestinal Oncology® - 9 month(s) ago
Physicians’ Education Resource®, LLC (PER®), is pleased to present the 2023 Gastrointestinal Oncology Conference, the 20th Annual Meeting of the International Society of Gastrointestinal Oncology® (ISGIO), a 2-day, multidisciplinary educational conference dedicated to presenting and discussing the latest advances in the broad field of gastrointestinal (GI) cancer research, as well as critical…
Source: event.gotoper.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Join me and world-renowned #GIcancer experts on October 13-14 for the 20th Annual Meeting of the International Society of Gastrointestinal Oncology® (ISGIO)! Register here and use my last name as a code to receive FREE registration https://t.co/nYxGeptHpS https://t.co/48Y1SFQje5
-
-
Mashup Score: 1Early Onset Colorectal Cancer Resources HUB | **What's new for colorectal cancer treatment - 11 month(s) ago
**What’s new for colorectal cancer treatment? ** Presnted by Tanios Bekaii-Saab, MD, Mayo Clinic, AZ First slide https://www.youtube.com/watch?v=z7pkLsLSVDE
Source: www.facebook.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @fireflyann: patient friendly great slides posted in 3 groups already! https://t.co/M6n18d56yz
-
RT @Ahn_Daniel_Onc: @fireflyann @CCR_AACR @MayoCancerCare @GIcancerDoc Sorry. Here you go! https://t.co/3pCb05RKfb